European markets are seen opening higher on Wednesday, brushing off concerns ahead of the U.S. Federal Reserve's first policy meeting of 2015.» Read More
*Deal boosts Roche presence in respiratory medicine. LONDON/ ZURICH, Aug 24- Roche Holding AG has agreed to buy U.S. biotech company InterMune Inc for $8.3 billion in cash, marking the latest multibillion-dollar deal in a consolidating pharmaceutical sector.
Biotech firm Roche announced plans Sunday to buy InterMune for $8.3 billion on a fully diluted basis in an all-cash transaction.
LONDON, Aug 24- Roche Holding AG has agreed to buy U.S. biotech company InterMune Inc for $8.3 billion in cash, marking the latest multibillion-dollar deal in a consolidating pharmaceutical sector, Roche said on Sunday.
SAN FRANCISCO, Aug 22- Genentech Inc is on the hunt for partnerships and investment opportunities in medical-technology startups, Chief Executive Officer Ian Clark told Reuters, underscoring the industry's growing interest in digital healthcare.
Asian equities traded mixed on Monday as a cautious sentiment set in after fresh conflict in Ukraine at the weekend.
Chugai denied over the weekend that it was in talks with Roche over a buyout but investors dismissed the statement, sending the shares limit-up in early trade, to a record 4,015 yen, before closing up 15.4 percent at 3,825 yen.
TOKYO, Aug 18- Japan's Nikkei ended flat on Monday in thin trade as geopolitical tensions dulled risk appetite, but Chugai Pharmaceutical jumped on a media report that Roche Holding AG's may be close to sealing a deal to take full ownership of the Japanese drugmaker. The Nikkei was flat at 15,322.60 in choppy trade.
Chugai shares rose 21 percent following a media report that Roche Holding AG is in talks to buy the almost 40 percent stake in the Japanese firm.
Milind Sabnis, Associate Director for Healthcare Practice at Frost & Sullivan, discusses news that Roche is looking to acquire Japanese drug giant Chugai Pharmaceutical for about $10 billion.
TOKYO, Aug 18- Japan's Nikkei was choppy on Monday morning as geopolitical tensions checked risk appetite, but Chugai Pharmaceutical jumped on a media report that Roche Holding AG's may be close to sealing a deal to gain full ownership of the Japanese drugmaker.
LOS ANGELES, Aug 17- Biotech drug production techniques based on plants, which may prove to be faster, higher yielding and cheaper than current methods using mammalian cells, haven't caught on with the biggest pharmaceutical companies.
NORWICH, England, Aug 17- Pampering leafcutter ants with fragrant rose petals and fresh oranges may seem an unlikely way to rescue modern medicine, but scientists at a lab in eastern England think it's well worth trying.
TOKYO, Aug 17- Chugai Pharmaceutical Co Ltd has denied a media report saying Roche Holding AG is in talks to buy the almost 40 percent stake in the Japanese company that it does not already own for about $10 billion. The Japanese firm, in a news release late on Saturday, said the media report "is not based on any announcement made by Chugai or Roche."
*VIX jumps on Russia, Ukraine concerns. NEW YORK, Aug 15- U.S. stocks ended mixed on Friday, paring an earlier selloff sparked by reports of Ukraine shelling a Russian armored column.
U.S. stocks ended the week mixed after news of fresh conflict between Russia and Ukraine.
Take a look at some of Friday's midday movers:
A spokeswoman for Roche declined to comment on the report. There has long been speculation that Roche might swallow Chugai- following a similar buyout of U.S. biotech group Genentech in 2009- to maximise exposure to the Japanese drugs market, the world's second largest after the United States.
Aug 15- Gilead Sciences Inc said an arbitration panel rejected Roche Holding AG's patent infringement claims related to Gilead's hepatitis C drug, Sovaldi.
Aug 15- Roche Holding AG is in talks to buy the almost 40 percent stake in Japan's Chugai Pharmaceutical Co Ltd that it does not already own for about $10 billion, Bloomberg reported, citing people familiar with the matter.
Aug 15- Achillion Pharmaceuticals Inc said all patients treated with its experimental hepatitis C drug showed no detectable levels of the virus four weeks after the therapy, sending its shares up 18 percent. Achievement of 100 percent cure rate confirms the competitive profile of NS5A, Wells Fargo Securities analyst Brian Abrahams wrote in a note.